Tandem Diabetes Care, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Tandem Diabetes Care, Inc. (TNDM) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2024-02-21
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2022-09-30 was 937.00 shares, a 99.41% decline year-over-year.
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2022-06-30 was 958.00 shares, a 99.35% decline year-over-year.
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-09-30 was 159.00K shares.
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-06-30 was 148.00K shares.
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 0.00 shares.
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2021 was 157.00K shares.
- Tandem Diabetes Care, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2020 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-21 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2024-02-21 | |||
| 2022-09-30 | 937.00 shares 10-Q · filed 2023-11-01 | 959.00 shares 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | 958.00 shares 10-Q · filed 2023-08-03 | 965.00 shares 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | 157.00K shares 10-K · filed 2024-02-21 | |||
| 2021-09-30 | 159.00K shares 10-Q · filed 2022-11-02 | 152.00K shares 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | 148.00K shares 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | 0.00 shares 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |